How do cells know when to activate or slow down their activity? A team from the University of Geneva (UNIGE) provides new insights by studying TORC2, an essential but still poorly understood protein complex. Using ultra-high-resolution imaging, scientists were able to observe its structure in detail for the first time. The team notably reveals the existence of a  molecular “cork” that controls its activation at the cell surface. Published in the journal Molecular Cell, these findings pave the way for new strategies to target this mechanism, which is involved in diseases such as cancer and diabetes.

This article introduces a no-code online platform for Optical Coherence Tomography (OCT) research and cancer diagnostics. It allows users to generate realistic digital OCT phantoms to benchmark various signal processing methods. Additionally, the platform provides advanced multimodal processing to extract optical attenuation, speckle contrast, depolarization, and strain maps. Its effectiveness in improving tumor margin visualization is successfully demonstrated using real brain, skin, endometrial, and murine cancer data.

Breast cancer is the most common malignancy among women worldwide. About 10% of breast cancers are hereditary, and approximately 60% of these cases carry BRCA1 or BRCA2 mutations. Individuals harboring BRCA1 mutations exhibit a markedly increased risk of developing breast cancer. BRCA1 plays a critical role in maintaining genomic stability by repairing DNA double strand breaks (DSBs) through homologous recombination (HR).

Metabolic tumor volume--a biomarker derived from PET imaging--can more accurately predict progression-free survival for large B-cell lymphoma patients than the widely used International Prognostic Index. By identifying patients who are more likely to have poor outcomes early, the PET biomarker can contribute to the individualization of therapies. This research was published in The Journal of Nuclear Medicine.

Device developed at the University of São Paulo aims to enable rapid and accessible diagnosis of pancreatic cancer, thereby increasing the chances of effective treatment.

A tumor-specific enhancer on extrachromosomal DNA drives MYC expression, revealing a new therapeutic target in high-risk pediatric medulloblastoma.